Kornimate/medical-research-clean huggingface dataset:
varenicline or nicotine patch in promoting smoking cessation among current smokers

Conditions: Tobacco Use Disorder

Summary: this pilot clinical trial studies varenicline or nicotine patch in promoting smoking cessation among current smokers. varenicline or nicotine patch may help people stop smoking

primary objectives: i. to determine if mail delivery of 12 weeks of varenicline results in improved smoking cessation outcomes relative to nicotine replacement therapy (nrt) in 300 smokers. ii. to determine if delivery of varenicline is cost-effective as compared to nicotine patch. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients undergo general smoking cessation counseling and receive varenicline orally (po) twice daily (qd) on days 1-28. courses repeat every 28 days for up to 12 weeks. arm ii: patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks. after completion of study treatment, patients are followed up at 4 months.

Eligibility criteria:
inclusion criteria: * cigarette smokers who call the new york state smokers' quitline requesting assistance with quitting smoking * state that they are under the care of a primary care physician * are eligible for receipt of pharmacotherapy by mail using the standard nrt criteria * speak english * answer "no" to the following 3 questions: * "have you ever been diagnosed with or treated for a mental health problem like major depression, bipolar disorder, dysthymia, or schizoaffective disorder?" * "have you ever had serious thoughts of killing or hurting yourself, ever have any intention or plan to carry out these thoughts, or actually attempted to kill yourself?" * "is there any reason that you cannot use varenicline/chantix?" exclusion criteria: * state that they are not under the care of a primary care physician * are not eligible for receipt of pharmacotherapy by mail using the standard nrt criteria * do not speak english * answer "yes" to the question, "have you ever been diagnosed with or treated for a mental health problem like major depression, bipolar disorder, dysthymia, or schizoaffective disorder?" * answer "yes" to the question, "have you ever had serious thoughts of killing or hurting yourself, ever have any intention or plan to carry out these thoughts, or actually attempted to kill yourself?" * answer "yes" to the question, "is there any reason that you cannot use varenicline/chantix?" * are women who are currently pregnant * report that they are unwilling to receive or take varenicline on screening
xience v everolimus eluting coronary stent system (eecss) china: post-approval, single-arm study

Conditions: Angioplasty; Chronic Coronary Occlusion; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis

Summary: this is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in china. the purpose of this study is to: * evaluate the continued safety and effectiveness of the xience v eecss in a cohort of real-world patients receiving the xience v eecss during commercial use * evaluate patient compliance to dual antiplatelet therapy (dapt)


Eligibility criteria:
inclusion criteria: * the patient or patient's legally-authorized representative agrees to participate in this study by signing the ethics committee-approved informed consent form (icf). * only xience v stent(s) is/are implanted into the coronary vasculature during the index procedure. exclusion criteria: * the inability to obtain a signed icf

Keywords: drug eluting stents stents china des xience v eecss
study evaluating flexitouch plus with connectivity on compliance in 30 patients with breast cancer-related lymphedema.

Conditions: Breast Cancer Lymphedema

Summary: the objective of this study is to demonstrate the feasibility of using the flexitouch plus with cellular connectivity (ft-cc) to monitor device use data to determine if reminders to patients impact compliance, and to identify the impact device compliance has on arm girth, quality of life (qol), and symptom assessment.

this is a multi-center, on label, prospective, randomized, two-arm feasibility study that plans to enroll 30 female subjects in the united states. in an effort to reduce potential exposure to covid-19, all study assessments are intended to be performed in a contactless manner (i.e., telephone, video conference, etc). if a subject passes the initial screening requirements via medical history and expresses interest in the study an informed consent form will be provided to them. once consent has been obtained they will undergo a baseline visit where they will be randomized to one of two treatment groups: passive ft-cc (text messages reminders will not be sent to subjects) and active ft-cc (text messages reminders will be sent if subject does not use the device for 2 consecutive days). randomization was incorporated into the study to determine if active ft-cc affects device use. a total of 2 follow-up visits will be conducted over a 60-day period.

Eligibility criteria:
inclusion criteria: 1. female 18 years of age or older 2. diagnosis of unilateral breast cancer-related lymphedema 3. willing and able to give informed consent (remotely or in person) 4. willing and able to comply with the study protocol requirements and all study-related visit requirements, including the ability to participate remotely 5. willing and able to receive text messages from sponsor exclusion criteria: 1. in-home use of pcd within previous 3 months 2. phase-one cdt within previous 1 month or planned phase-one cdt during study participation phase-one cdt defined as professionally administered mld and/or multi-layer short stretch compressive bandaging. 3. inability to be fit for pcd garments 4. heart failure (acute pulmonary edema, decompensated acute heart failure) 5. acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism) 6. active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin or untreated inflammatory skin disease) on the arms or trunk 7. currently receiving treatment for cancer with curative intent. 8. any circumstance where increased lymphatic or venous return is undesirable 9. currently pregnant or trying to become pregnant 10. known inability to receive cell phone connection where ft-cc therapy will be administered
comparison of cy-atg vs cy-flu-atg for the conditioning therapy in allo-hct

Conditions: Bone Marrow Failure Syndromes

Summary: randomized comparison of cyclophosphamide versus reduced-dose cyclophosphamide plus fludarabine in addition to anti-thymocyte globulin for the conditioning therapy in allogeneic hematopoietic cell transplantation for bone marrow failure syndrome.

this is a prospective, randomized, non-blind study. conditioning therapy will start on day -5 in patients who are randomized to receive cy+atg. hydration with 0.45% nacl at 6 liters/24 hours will be started on day -5. cy 50 mg/kg in d5w 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter. mesna 12 mg/kg iv push immediately before cy and 3, 6, 9, and 12 hours after cy. thymoglobuline 3 mg/kg in n/s 500-800 ml (less than 0.5 mg/ml) or lymphoglobuline 15 mg/kg in n/s 500-800 ml (less than 2 mg/ml) iv daily at 8 am on days -4 to -2. premedication for atg (alg) will include methylprednisolone 2 mg/kg iv infusion, tylenol 600 mg po, and avil 45.5 mg iv push. the doses of cyclophosphamide and atg (alg) will be calculated using actual body weight. conditioning therapy will start on day -6 in patients who are randomized to receive cy+fludarabine (fludaraâ®, berlex laboratories, richmond, ca)+atg. fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in d5w 100 ml for 5 consecutive days (days -6 to -2). thymoglobuline 3 mg/kg in n/s 500-800 ml (less than 0.5 mg/ml) or lymphoglobuline 15 mg/kg in n/s 500-800 ml (less than 2 mg/ml) iv daily at 8 am on days -4 to -2. premedication for atg (alg) will include methylprednisolone 2 mg/kg iv infusion, tylenol 600 mg po, and avil 45.5 mg iv push. hydration with 0.45% nacl at 6 liters/24 hours will be started on day -3. cy 50 mg/kg in d5w 200 ml i.v. over 1-2 hours on days -3 to -2 by pump through a central venous catheter. mesna 12 mg/kg iv push immediately before cy and 3, 6, 9, and 12 hours after cy. the doses of cyclophosphamide and atg (alg) will be calculated using actual body weight.

Eligibility criteria:
inclusion criteria: * patients with bone marrow failure syndrome. * written informed consent must be obtained from the patients and donors. * patients should have an hla-identical or one-locus mismatched sibling, family or unrelated donor who is 60 years or less. * patients should be 15 years of age or older, but younger than 60 years. * the performance status of the patients should be 70 or over by karnofsky performance scale (see appendix i). * patients should not have major illness or organ failure. * patients must have adequate hepatic function (bilirubin less than 2 mg/dl, ast and alt less than three times the upper normal limit). * patients must have adequate renal function (creatinine less than 2.0 mg/dl). * patients must have adequate cardiac function (ejection fraction \> 45% on muga scan). * patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlikely, and making informed consent impossible. * patients must not be in pregnancy. exclusion criteria: * patients should have major illness or organ failure
virtual reality as a motor priming tool for cognitive-motor rehabilitation among sub-acute stroke patients

Conditions: Stroke

Summary: stroke is the second leading global cause of mortality counting for 6.5 million deaths per annum. the global prevalence of stroke is increasing with an estimated prevalence of 33 million per year, affecting 1 out of 6 individuals during their lifetime. the international data suggests the overall economic burden in asia is projected to be increased to 1.3 billion by 2050. therefore, the appropriate and timely stroke intervention is required to save healthcare costs and reduce the burden of the disease. studies have reported the effectiveness of vr intervention not only in cognitive abilities but it has found to be simultaneously effective in improving other domains as attention and coordination with motor retraining. vr combined with a newly developed concept of motor priming has shown encouraging results in improving motor control and task execution in stroke patients. further studies are needed to analyze the impact of motor priming with vr in stroke patients on varied neurological domains; hence the present study aims to investigate the impact of vr based motor priming on sensorimotor, functional and cognitive outcomes among sub-acute stroke patients rehabilitation.

a total 62 patients will be recruited in the study. after voluntary consent, all the patients will be randomly divided into group-a and b through the envelope method of simple random sampling. patients in group-a will be receiving vr based motor priming intervention while group-b patients will be receiving motor-relearning program as conventional therapy. whereas, both the groups will be given 16 sessions of their respective protocol, comprising of 45 minutes, 4 times/week for the duration of 4 weeks. pre and post assessment will be performed for each patient on all three quantitative outcome measures i.e. fma-ue, cahai-13, and moca. a trial will be terminated, if the patient reported fatigue of \>8 out of 10 on the visual analogue scale, unable to execute movements, reports pain, eye strain, or signs of volitional fatigue in hemiplegic or non-hemiplegic extremities.

Eligibility criteria:
inclusion criteria: * male and female stroke patients aged 25-65 years * patients who had an ischemic or hemorrhagic stroke in sub-acute phase of \< 3 months * mild cognitive impairment i.e. \< 26 (19.0-25.2) on moca * minimum scoring of 28 in the motricity index exclusion criteria: * diagnosed visual-perceptual ailments which may restrict task execution * communication disorders such as aphasia or dysarthria which may impede cognitive assessment * comorbidities such as elevated blood pressure (\>160mmhg/105 mmhg), heart diseases or chronic medical conditions * major or active psychological illness and pre-existing dementia
application of 68ga-pentixafor pet/ct for thymoma

Conditions: Thymoma

Summary: chemokine receptor cxcr4 was expressed in t cells and cxcr4-targeting molecular imaging- 68ga-pentixafor pet/ct could be a promising technique to evaluate the extent of thymoma with higher accuracy. this prospective study is going to investigate whether metabolic characterization by 68ga-pentixafor pet/ct may be superior for diagnosis, distinguish evaluation for thymoma.

thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma also might have myasthenia gravis (mg). because of the scarcity and complexity of mg-associated thymoma, its pathogenesis and etiology still remain unclear nowadays. the expression of c-x-c chemokine receptor type 4 (cxcr4) is absent or low in most healthy tissues but highly expressed in various types of tumors. cxcr4 might contribute to the clinical cancer progression, and cxcr4 could be a valuable prognostic biomarker in the therapy of mg-associated thymoma.

Eligibility criteria:
inclusion criteria: * suspected or confirmed untreated thymoma patients * signed written consent. exclusion criteria: * pregnancy * breastfeeding * known allergy against pentixafor * any medical condition that in the opinion of the investigator,may * significantly interfere with study compliance.
assessment of total coronary circulation time using timi frame count method (tcct-timi)

Conditions: Coronary Angiography; Coronary Artery Disease; Coronary Artery Ectasia; Slow-Flow Phenomenon; Coronary Heart Disease

Summary: the aim of this study is to evaluate and describe the total coronary circulation time (tcct) by using timi frame count method in patients performed coronary angiography. tcct is described as an angiographic index which is the sum of the frame count of coronary artery and venous system. this study also evaluates the relationship between the diseases in arterial system such as coronary artery ectasia, coronary slow flow, coronary artery disease and coronary venous pathologies.


Eligibility criteria:
inclusion criteria: * patients whom performed coronary angiography with a suspicion of coronary artery disease exclusion criteria: * history of cerebrovascular disease, chronic inflamatuar disease, malignity, chronic kidney and hepatic disease
turkish version of the sitting balance scale

Conditions: Stroke

Summary: the aim of this study is to investigate the validity and reliability of the turkish version of the sitting balance scale in stroke patients.

the sitting balance scale is primarily designed to measure the sitting balance in fragile elderly individuals who cannot stand up. it has also been validated in individuals with stroke and consists of 11 items. each item is graded from 0 to 4. the highest score that can be obtained is 44. low test scores indicate impaired sitting balance. the necessary permissions were obtained from the authors for the balance of sitting scale, whose validity and reliability features will be tested, and the questionnaire was finalized by completing the translation process into turkish. the basis of the use of special instruments such as scales is to prove their usability in the sample group to which the instrument will be applied. the first step for this is the translation from the original language to another language. during the translation process into turkish, two experts who have good command of english translated the questionnaire from english to turkish. these translations were translated back into turkish by two native speakers and distant medical subjects. in addition, these translations were re-examined by the researchers and turned into a single form. this form, which was sent to five experts in the field, was checked for content and its suitability for turkish was evaluated. with the opinion of experts, the scale took its final form. the study will include individuals over the age of 18 who applied to kastamonu training and research hospital and diagnosed with ischemic or hemorrhagic stroke.

Eligibility criteria:
inclusion criteria: * being 18 years or older, * diagnosis of stroke, * not having a cooperation and communication problem, * at most 6 months have passed after stroke. exclusion criteria: * other neurological or orthopedic problems that affect functionality and balance other than stroke. * having advanced cardiovascular disease and contraindication for mobilization
utility of the clamping bean test (cbt) for covert hepatic encephalopathy screening

Conditions: Hepatic Encephalopathy; Covert Hepatic Encephalopathy

Summary: hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or porto-systemic shunt. it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. according to the symptoms, it is classified as covert he (che) and overt he (ohe). che can progress to ohe and is associated with reduced driving ability, increased risk of accidents and hospitalization and weakened health-related quality of life, resulting in poor prognosis and socio-economic status. however, due to the absence of readily identifiable clinical symptoms and signs, che is often neglected in clinical practice. presently, the diagnosis of che depends on psychometric and neurophysiological tests, including the psychometric hepatic encephalopathy score (phes), critical flicker frequency (cff) test, continuous reaction time (crt) test, inhibitory control test, the scan test, and electroencephalography. among them, phes is most widely used and recommended by several guidelines. however, it is difficult to screen che among all cirrhotic patients in the clinic using phes because of the time required and a dependence on trained experts. moving beans from one container to another with tweezers involves dexterity, agility and coordination.the hypothesis was that the utility of the clamping bean test (cbt) will enable early screening patients with che.


Eligibility criteria:
inclusion criteria: * written informed consent; * age 18-70 years old; * patients with clinical diagnosis of liver cirrhosis and without current ohe. exclusion criteria: * presence of other uncontrollable neuro-psychiatric or neurological diseases that affect cognitive function, such as alzheimer's disease, parkinson's disease, schizophrenia, etc.; * clinically diagnosed as overt hepatic encephalopathy(ohe); * consumption of hypnotic or sedative drug and psychotropic drug in the past 4 weeks; * alcohol consumption \>50 g/day within the past 3 months; * conditions preventing the patient from completing the test independently (for instance, red-green color blindness, difﬁculty in comprehension).
registry of pancreatic exocrine insufficiency.

Conditions: Exocrine Pancreatic Insufficiency

Summary: a prospective, cross-sectional, observational study has been designed with the aim of the study is to evaluate the diagnosis and management of patients with pancreatic exocrine insufficiency secondary to different pancreatic diseases and conditions in clinical practice. a registry has been develop to include patients older than 18 years diagnosed with pancreatic exocrine insufficiency, sho are willing to participate in the study and sign the informed consent. registry includes demographics, toxic habits,pharmacological therapies, underlying disease that causes pancreatic exocrine insufficiency.


Eligibility criteria:
inclusion criteria: * patients older than 18 years diagnosed with pei secondary to pancreatic diseases, pancreatectomy, or gastrectomy. * willingness to participate in the study. exclusion criteria: * patients with pancreatic diseases without pei. * pregnancy * known allergy to oral pancreatic enzymes * any condition avoiding adequate clinical management of pei. * patients who are not willing to participate in the study.
a pilot trial of manlikang in reducing salt intake and blood pressure among patients with hypertension

Conditions: Hypertension; Hypertension With Abnormal Renal Function

Summary: this study is a single arm trial with before-after comparison design. three groups of patients with hypertension will be recruited: not taking antihypertension drugs and having normal renal function, taking antihypertension drugs and having normal renal function, and having abnormal renal function without regards of antihypertension drugs use. each group includes 30 patients. based on renal function test, the investigators provide the manlikang containing potassium chloride to patients with normal renal function, and provide the manlikang not containing potassium chloride to patients with abnormal renal function. all hypertension patients will use the formula salt with very low sodium (manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks. the primary outcome will be the decrease of patients' systolic blood pressure at the end of the trial.


Eligibility criteria:
inclusion criteria: * 50 to 75 years old * no planning to move out of the community in the next three months * not cooking at home less than 3 times or one day during the study * willing to participate in the study and sign informed consent exclusion criteria: * acute myocardial infarction, history of stroke in the past 3 months, history of malignancy or expected lifetime less than 1 year. * hypercortisolism or aldosteronism * acute disease, such as upper respiratory infection, fever and diarrhea. * incapable of communicating, such as deaf and dumb, dementia, mental disorder. * families taking salt substitute currently * not willing to use manlikang in family * liver disfunction * anyone with abnormal serum potassium in family * anyone using potassium-retaining diuretics in family